A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea

Dova Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Rosacea

Treatments: Drug: Vehicle; Drug: IDP-115

Study type: Interventional

Funder types: Industry

Identifiers

NCT00667173

DPSI-IDP-115-P2-01

Details and patient eligibility

About

The purpose of this study is to assess the safety and effectiveness of IDP-115 in treating patients with rosacea.

Enrollment: 140 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Presence of facial rosacea
• Presence of inflammatory lesions

Exclusion criteria

• Dermatological conditions of the face that could interfere with clinical evaluations
• Known history of photosensitivity disorders (such as lupus erythematosus or polymorphous light eruption)
• Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

140 participants in 3 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: IDP-115

2

Placebo Comparator group

Treatment:

Drug: Vehicle

Drug: Vehicle

3

Placebo Comparator group

Treatment:

Drug: Vehicle

Drug: Vehicle